<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306110</url>
  </required_header>
  <id_info>
    <org_study_id>FS02-062007</org_study_id>
    <nct_id>NCT01306110</nct_id>
  </id_info>
  <brief_title>Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study</brief_title>
  <acronym>DIABSCAN</acronym>
  <official_title>Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association HGE CHU Bordeaux Sud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association HGE CHU Bordeaux Sud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate liver fibrosis using FibroScan and biochemical markers
      in patients with diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with diabetes are at risk for nonalcoholic fatty liver disease (NAFLD) leading to
      advanced fibrosis, cirrhosis, and liver cancer. However, liver fibrosis screening in this
      large population needs non-invasive methods. Recently, FibroScan was shown to be a good
      method for the diagnosis of advanced fibrosis in NAFLD patients. We examined the efficacy of
      a screening strategy with a noninvasive fibrosis biomarker (FibroTest) and transient
      elastography (FibroScan) in patients with diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">277</enrollment>
  <condition>Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diabetes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects

          -  More than 18 years of age

          -  Patients with Diabetes

          -  Written informed consent

        Exclusion Criteria:

          -  Patients refusing to participate to the study and to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor De Ledinghen, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juliette Foucher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien Vergniol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent Rigalleau, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service Hepato-Gastroent√©rologie Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Association HGE CHU Bordeaux Sud</investigator_affiliation>
    <investigator_full_name>de Ledinghen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Liver fibrosis</keyword>
  <keyword>diabetes</keyword>
  <keyword>Fibroscan</keyword>
  <keyword>Fibrotest</keyword>
  <keyword>noninvasive fibrosis biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

